Detalhe da pesquisa
1.
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
Lancet Oncol
; 23(1): 53-64, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34838156
2.
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Cancer
; 128(5): 966-974, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34784056
3.
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Invest New Drugs
; 39(1): 163-174, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32737717
4.
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Lancet Oncol
; 19(3): 405-415, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29439857
5.
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors.
Invest New Drugs
; 32(3): 445-51, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24271274
6.
PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells.
J Cell Mol Med
; 17(3): 377-85, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23387989
7.
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Cancer Res Commun
; 3(12): 2572-2584, 2023 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38115208
8.
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
Nat Med
; 29(5): 1103-1112, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37059834
9.
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
J Immunother Cancer
; 11(3)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36927527
10.
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.
Cancer
; 118(24): 6055-62, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22674198
11.
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
J Immunother Cancer
; 10(4)2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35444058
12.
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Eur Urol
; 82(4): 365-373, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35643589
13.
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.
J Immunother Cancer
; 10(10)2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36316061
14.
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
J Immunother Cancer
; 10(8)2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35940825
15.
Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer.
BJU Int
; 108(8 Pt 2): E245-9, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21320274
16.
mTOR inhibitors in renal cell carcinoma.
Therapy
; 8(4): 359-367, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21894244
17.
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
J Immunother Cancer
; 9(7)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34301808
18.
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
Eur J Cancer
; 145: 1-10, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33412465
19.
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
J Clin Oncol
; 39(26): 2914-2925, 2021 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34255535
20.
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.
J Clin Oncol
; 39(9): 1020-1028, 2021 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33529051